Eli Lilly and Co
XHAM:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
XHAM:LLY
Watchlist
Price: 911.6 EUR 2.81% Market Closed
Market Cap: 872B EUR

Operating Margin

44.4%
Current
Improving
by 10.4%
vs 3-y average of 34%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
44.4%
=
Operating Income
$26.4B
/
Revenue
$59.4B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
44.4%
=
Operating Income
€26.4B
/
Revenue
$59.4B

Peer Comparison

Country Company Market Cap Operating
Margin
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
519.1B USD
Loading...
US
Abbvie Inc
NYSE:ABBV
380.6B USD
Loading...
CH
Roche Holding AG
SIX:ROG
274.5B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
277.1B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Amgen Inc
NASDAQ:AMGN
182.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
158.6B USD
Loading...
US
Pfizer Inc
NYSE:PFE
146.2B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
109.7B USD
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.7B USD
Loading...
No Stocks Found

Market Distribution

Higher than 96% of companies in the United States of America
Percentile
96th
Based on 14 112 companies
96th percentile
44.4%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Eli Lilly and Co
Glance View

Eli Lilly and Co. has long been a stalwart in the pharmaceutical industry, sculpting its trajectory through innovation and strategic acumen. Founded in 1876 by Colonel Eli Lilly, the company has grown from a small chemical firm into a global powerhouse in developing life-changing medications. Its headquarters in Indianapolis, Indiana, serve as a hub of research and development, where groundbreaking scientific exploration meets business strategy. Eli Lilly thrives on its core pillars of innovation in oncology, immunology, and diabetes care, relying on a deep commitment to scientific discovery and patient care. This emphasis allows it to consistently bring cutting-edge treatments to market, boosting its reputation as a leader in pharmaceuticals and maintaining a strong pipeline of drugs that drive future growth. The company's business model is principally built around creating proprietary medications that command premium pricing due to their uniqueness and effectiveness. This model sustains Eli Lilly's revenue through a dual approach: serving mature markets with established products and fueling growth with new launches. Patents on flagship drugs protect these revenue streams, allowing the company to invest substantially in research and development, which in recent years prioritizes personalized medicine and biotechnology. Collaborations with academic institutions and other corporations have also been pivotal, accelerating drug development and expanding Eli Lilly's reach across therapeutic areas. Overall, its ability to navigate regulatory frameworks and maintain robust sales and marketing strategies ensures its medications reach patients globally, securing its financial health and influence within the healthcare landscape.

LLY Intrinsic Value
354.21 EUR
Overvaluation 61%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
44.4%
=
Operating Income
$26.4B
/
Revenue
$59.4B
What is Eli Lilly and Co's current Operating Margin?

The current Operating Margin for Eli Lilly and Co is 44.4%, which is above its 3-year median of 34%.

How has Operating Margin changed over time?

Over the last 3 years, Eli Lilly and Co’s Operating Margin has increased from 29.3% to 44.4%. During this period, it reached a low of 26.4% on Mar 31, 2023 and a high of 44.4% on Sep 30, 2025.

Back to Top